eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
. (image: rex/shutterstock)
.
.
.
.
advertisement
.
.
experts say years of cuts to nhs budgets and staff has led to patients waiting longer for chemotherapy and radiotherapy.
.